Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, mood stabilizers, stimulants, and weight-loss drugs.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Aja Beckett quit her job after her app for tracking weight-loss shots, Shotsy, took off on Reddit.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...